

## **Summary of Staff Education Resources**

Effective Date: 9/30/16

Title/Publication Date	Agency	Description	Link	Notes
Treating Opioid Addiction as a Chronic Disease	American Society of Addiction Medicine (ASAM)	Discusses opioid epidemic and the need to recognize addiction as a disease needing long-term management. Presents issues about underutilization of medications and removing barriers to treatment. (2 pages)	http://www.asam.org/docs/default- source/advocacy/cmm-fact-sheet11-07- 14.pdf?sfvrsn=0	Basic review appropriate for all levels of staff.
Medication-Assisted Treatment for Opioid Addiction (2016)	Legal Action Center	Distinguishes between myths and facts related to medication-assisted treatment of opioid addiction. (2 pages)	https://lac.org/wp- content/uploads/2016/02/Myth-Fact-for- MAT.pdf	Basic review appropriate for all levels of staff.
Drug Court Practitioner Fact Sheet (2002)	National Drug Court Institute	Provides information on methadone maintenance and other pharmacological interventions for the treatment of opioids addiction. Includes discussion on use with special populations, comorbid disorders and cost effectiveness.	http://www.ndci.org/sites/default/files/ndci/MethadoneFactSheet.pdf	Comprehensive information on methadone treatment with some additional information on buprenorphine. Due to older publication date, naltrexone is not covered and information on LAAM is no longer relevant as this medication is no longer used. While clinical in nature, good overview for all staff as it breaks down a number of myths.
Extended-Release Naltrexone (2013)	National Drug Court Institute	Provides description of Extended-Release- Naltrexone. Provides discussion of how it works, how it is provided, special considerations, and use with criminal justice populations (3 pages)	http://www.ndci.org/publications/fact- sheets	While the brief is more clinical in nature, it could be used to educate operations staff on the benefits of this medication and how it differs in terms of concerns associated with diversion and abuse of medications.
Prescription Drug Abuse	National Institute on Drug Abuse (NIDA)	Provides information on commonly abused prescription drugs. Includes discussion on opioids, consequences of abuse, trends in use, addiction treatment, and prevention. (16 pages)	https://www.drugabuse.gov/publications/ research-reports/prescription- drugs/what-prescription-drug-abuse	Good resource for all staff and risks associated with prescription drugs for everyone, not just criminal justice clients. Due to length of document and number of topics, agencies should consider breaking coverage of the materials into smaller sections/topics.

Treatment Approaches for Drug Addiction (2016)	National Institute on Drug Abuse (NIDA)	Discusses research findings on effective treatment approaches for drug abuse and addiction. Provides principles of effective treatment. (7pages)	https://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drugaddiction	Intermediate review appropriate for all levels of staff.
Buprenorphine: Treatment for Opiate Addiction Right in the Doctor's Office (2006)	National Institute on Drug Abuse (NIDA)	Brief discussion of opiate addiction in the U.S. and Buprenorphine's contributions to addiction treatment.	https://www.drugabuse.gov/sites/default/files/bupren.pdf	Basic review appropriate for all levels of staff; however, information on buprenorphine is limited given date of this publication. More recent publications can provide additional information.
Heroin (2014)	National Institute on Drug Abuse (NIDA)	Provides details on what heroin is, how it is used, effects on body, treatments, at risk populations, and what can be done for overdose. (8 pages)	https://www.drugabuse.gov/publications/ research-reports/heroin/letter-director	Intermediate review appropriate for all levels of staff.
Medication-Assisted Treatment for Opioid Addiction (Topics in Brief) (2012)	National Institute on Drug Abuse (NIDA)	Provides information on role of medications for the treatment of opioid addiction. Discusses numbers of people addicted, types of medication to treat opioid addiction, and benefits of these medications. (2 pages)	https://www.drugabuse.gov/sites/default/files/tib mat opioid.pdf	Basic review appropriate for all levels of staff.
Prescription Opioids and Heroin (2015)	National Institute on Drug Abuse (NIDA)	Provides overview of the problem and the link between prescription opioid use and heroin use.  Discusses risk factors for each and the need for both prevention and treatment. Also outlines national efforts to increase access to MAT. (8 pages)	https://www.drugabuse.gov/sites/default/files/rx and heroin rrs layout final.pdf	Basic review appropriate for all levels of staff. Although 8 pages in length, it is just over 5 pages in content.
The Prescription Opioid Addiction Treatment Study (POATS): Treatment Strategies for Prescription Opioid Dependence	National Institute on Drug Abuse (NIDA)	Describes how buprenorphine works and presents the results of the National Drug Abuse Clinical Trials Network (CTN) study comparing brief and extended buprenorphine treatments for individuals addicted to prescription opioids. (2 pages)	https://www.drugabuse.gov/sites/default/files/files/BupPOATS Factsheet.pdf	Basic review appropriate for all levels of staff, but geared toward clinical staff. Study was not on CJ populations or in CJ environments, but does provide argument that longer time on medication produces better outcomes.
Buprenorphine Treatment: Training for Multidisciplinary Addiction Professionals	National Institute on Drug Abuse (NIDA)	This provides a brief overview of buprenorphine, its effects in clinical settings when used to treat opioid addiction, and the role of non-physician practitioners in providing and supporting treatment. (2 pages)	https://www.drugabuse.gov/sites/default/files/files/BupTx Factsheet.pdf	While this is a basic review appropriate for all levels of staff working in criminal justice, the materials are geared toward non-physicians who work in office-based primary care settings and advocates for them to access a NIDA/SAMHSA Blending Initiative6-module training package.
Buprenorphine: Easier Opioid Withdrawal and Treatment Available in Primary Care Settings (2012)	National Institute on Drug Abuse (NIDA)	Describes Buprenorphine and how it works, outlines the phases of Buprenorphine therapy, and identifies ideal candidates who might benefit from this medication. (2 pages)	http://www.attcnetwork.org/explore/prio rityareas/science/blendinginitiative/docu ments/poats/POATS_Buprenorphine_Fact Sheet.pdf	Basic review appropriate for all levels of staff. While the title targets primary care settings, it is appropriate for review by CJ professionals and includes information as to why counselors should not work at odds with MAT.

Methadone: Methadone maintenance treatment (MMT) can help injection drug users (IDUs) reduce or stop injecting and return to productive lives. (2012) Naltrexone: Naltrexone can reduce cravings and increase	National Institute on Drug Abuse (NIDA)  National Institute on Drug	Discusses basic information about Methadone and Methadone treatment programs. The stages of Methadone treatment are discussed. Some benefits and risks associated with Methadone are also presented. (2 pages)  This fact sheet discusses benefits and side effects associated with Naltrexone. Steps to increase	http://www.attcnetwork.org/projects/doc uments/poats/POATS_Methadone_FactSh eet.pdf  http://www.nattc.org/projects/document s/poats/POATS_Naltrexone_FactSheet.pdf	Basic review appropriate for all levels of staff. Includes information on length of methadone treatment necessary for patients, with some requiring methadone for indefinite period of time. Stresses that decisions about dose and length of time on medication are decisions to be made by medical professionals.  Basic review appropriate for all levels of staff.
abstinence for individuals dependent on opioids or alcohol. (2012)	Abuse (NIDA)	treatment outcome are discussed as well as who is best suited to take Naltrexone for Opioid addiction. The different forms of Naltrexone are presented as well as situations where Naltrexone should not be taken. (2 pages)		
Medication-Assisted Treatment for Opioid Addiction (2012)	Office of National Drug Control Policy	General discussion of medications approved by the U.S. Food and Drug Administration for use in treatment of opioid use disorder. Also discusses differences between using medications for detoxification, stabilization, and maintenance. (6 pages)	https://www.whitehouse.gov/sites/default/files/ondcp/recovery/medication_assisted treatment 9-21-20121.pdf	Basic review appropriate for all levels of staff. Discusses evidence in favor of medication maintenance for certain patients and highlights SAMHSA consensus group recommendation that patients never be coerced into tapering medication.
The facts about Buprenorphine for Treatment of Opioid Addiction (2014)	Substance Abuse and Mental Health Services Administration (SAMSHA)	Provides information about buprenorphine. Includes warnings, side effects, and basic information about addiction and treatment with buprenorphine (16 pages)	http://store.samhsa.gov/shin/content/SM A09-4442/SMA09-4442.pdf	While the document is messaged toward patients, it can serve as a good basic overview of buprenorphine treatment for staff. Basic overview appropriate for all levels of staff.
An Introduction to Extended- Release Injectable Naltrexone for the Treatment of People with Opioid Dependence (2012)	SAMHSA	Discusses the role that Extended-Release Injectable Naltrexone can have in the treatment of opioid dependence. Discusses how it differs from other forms of MAT, how it works, safety concerns, benefits, and use with other therapies (8 pages)	http://store.samhsa.gov/shin/content/SM A12-4682/SMA12-4682.pdf	Intermediate level review for clinical and management staff. 6 pages of content.
Adult Drug Courts and Medication-Assisted Treatment for Opioid Dependence (2014)	SAMHSA	Designed for Drug Court team. The goal is to increase the knowledge about the effectiveness of MAT and advocate for increased use in drug courts. Provides information the effectiveness of medication-assisted treatment and the opioid problem. (8 pages)	http://store.samhsa.gov/product/Adult- Drug-Courts-and-Medication-Assisted- Treatment-for-Opioid- Dependence/SMA14-4852	Intermediate level review appropriate for all levels of staff. While geared toward drug court professionals, relevant to anyone working in correctional treatment setting. 6 pages of content.